Premium
Patient‐reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer
Author(s) -
Chen Ronald C.,
Mamon Harvey J.,
Chen YuHui,
Gelman Rebecca S.,
Suh W. Warren,
Talcott James A.,
Clark Jeffrey W.,
Hong Theodore S.
Publication year - 2010
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24963
Subject(s) - medicine , diarrhea , colorectal cancer , abdominal pain , gastrointestinal cancer , cancer , radiation therapy
BACKGROUND: Although it is known that standard 5‐fluorouracil–based chemoradiation therapy for rectal cancer causes significant acute gastrointestinal (GI) toxicity, research on patient‐reported outcomes (PROs) is limited. The authors undertook the current study to assess the feasibility of incorporating PRO measurement into routine clinical practice and to describe the trajectory of symptom development during treatment. METHODS: Seventy‐seven consecutive patients who were treated between 2006 and 2008 were eligible. Patients completed the 7‐item Bowel Problems Scale immediately before weekly physician visits. RESULTS: The questionnaire completion rate was 95%. Individual GI symptoms had different trajectories of development. By Week 5, approximately 40% of all patients developed clinically meaningful pain, bowel urgency, or tenesmus that was not present during Week 1; 30% developed diarrhea, abdominal cramping, and passing mucus. However, overall symptom burden was moderate. Seventy‐five percent of patients who presented with rectal bleeding at Week 1 improved by Week 3 of treatment. Within each physician‐assessed grade of diarrhea, patient experience varied widely. For example, of the 50 patients who developed grade 2 diarrhea on the Radiation Therapy Oncology Group Acute Morbidity Scale, the numbers of patients reporting only occasional symptoms versus those reporting frequent or very frequent symptoms were similar. CONCLUSIONS: PROs provided information on patient symptoms during chemoradiation treatment for rectal cancer that was not captured otherwise, and it was feasible to incorporate PROs into routine clinical practice. The current results may be used by physicians to counsel their patients before treatment initiation and to provide a benchmark against which trials that use new therapies may be compared. Cancer 2010; 116:1879–86. © 2010 American Cancer Society.